Non-small cell lung cancer, constituting the majority of lung cancer diagnoses, remains a formidable adversary due to its heterogeneity and typically late-stage presentation. Immune checkpoint inhibitors (ICIs) have revolutionized treatment paradigms, yet predicting patient response and survival remains elusive. Against this backdrop, metabolic imaging using 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) emerges as a non-invasive approach that captures tumor glycolytic activity and burden—parameters that may reflect tumor aggressiveness and potential treatment resistance.

The retrospective study analyzed a cohort of 70 patients with stage III or IV NSCLC, all of whom underwent FDG-PET/computed tomography prior to initiation of first-line ICI–based combination therapy. The focus was on quantifying three primary metabolic metrics across all detectable lesions confined to the torso: maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion glycolysis (TLG). These indices were employed not only to delineate tumor burden but also to explore their prognostic significance.

A notable aspect of the study was the emphasis on MTV and TLG, volumetric measurements representing the metabolically active tumor volume and lesion glycolytic activity, respectively. Unlike SUVmax, which captures peak glucose uptake in the tumor but may not account for tumor heterogeneity, volumetric parameters potentially provide a more holistic view of disease burden and metabolic aggressiveness.

In univariate analyses, Eastern Cooperative Oncology Group performance status (PS), MTV-torso, and TLG-torso showed significant associations with both progression-free survival (PFS) and overall survival (OS). Performance status, a clinical measure evaluating a patient’s ability to perform ordinary tasks, understandably impacts prognosis. However, the coupling of this clinical index with volumetric PET parameters strengthens the predictive framework, suggesting that combining metabolic imaging with clinical features enhances risk stratification accuracy.

The multivariate models further distilled MTV-torso and PS as independent prognostic biomarkers. Patients exhibiting lower tumor metabolic volumes within the torso experienced substantially prolonged survival durations, with mean PFS extending to over 580 days compared to less than 160 days for their counterparts with higher MTV-torso values. Likewise, overall survival nearly quadrupled for those with lower metabolic tumor burden. Such stark contrasts underscore the power of MTV-torso as a prognostic indicator, reinforcing its potential integration into clinical decision-making algorithms.

Interestingly, SUVmax-torso failed to demonstrate a significant correlation with survival outcomes in this cohort. This finding aligns with emerging evidence cautioning against sole reliance on maximum uptake values, which may overlook the intricate spatial and metabolic heterogeneity of tumor masses. Consequently, the study advocates for increased emphasis on volumetric parameters when leveraging FDG-PET data for prognostication.

The clinical implications of these findings are profound. By incorporating MTV-torso assessments into routine FDG-PET analyses for NSCLC patients slated for combined immunotherapy and chemotherapy, clinicians might better identify individuals at higher risk of disease progression and mortality. This prognostic enrichment could, in turn, guide personalized therapeutic intensification, closer monitoring protocols, or enrollment into clinical trials exploring novel agents.

Moreover, the focus on torso-based lesions—encompassing primary tumors and metastatic deposits within the chest, abdomen, and pelvis—reflects a realistic appraisal of disease dissemination patterns in advanced NSCLC. The metabolic tumor burden within this anatomical region serves as a representative surrogate for overall tumor load, streamlining imaging assessment and optimizing prognostic utility.

The methodology employed in this research is notable for its rigorous quantitative image analysis, providing replicable and objective metrics that transcend subjective interpretations. Utilizing Cox proportional hazards regression and Kaplan-Meier survival estimates ensured robust statistical assessments, enhancing the reliability of conclusions drawn. The retrospective design, while typical for such exploratory investigations, sets the stage for prospective validation studies to cement clinical applicability.

Beyond immediate prognostication, the study’s revelations about FDG-PET volumetric parameters may inspire further exploration into their role as predictive biomarkers for immunotherapy responsiveness. As the landscape of NSCLC treatment evolves, uncovering imaging correlates of immune activation or resistance could revolutionize patient selection and therapeutic tailoring, maximizing benefits while minimizing unnecessary toxicity.

This research also serves as a testament to the synergetic potential of multi-disciplinary collaboration, intertwining nuclear medicine, oncology, radiology, and biostatistics to unravel complex biological phenomena. The precision measurement of metabolic tumor burden unveils previously underappreciated dimensions of NSCLC biology, fostering a nuanced understanding capable of driving clinical innovation.

As we stride deeper into the era of personalized medicine, the integration of advanced imaging biomarkers like MTV-torso alongside molecular and genomic profiling promises to refine prognostic models substantially. The capacity to stratify patients not only on histopathological grounds but also on spatial and metabolic tumor characteristics heralds a future where therapies are meticulously calibrated to individual disease landscapes.

While challenges remain, including the need for standardized imaging protocols, harmonization of volumetric PET metrics across centers, and longitudinal validation, the promising results reported by Obata et al. undoubtedly galvanize the oncology community. These findings illuminate a path toward enhanced prognostic precision in advanced NSCLC, leveraging routinely acquired imaging data to inform pivotal clinical decisions.

In conclusion, the study convincingly positions torso-metabolic tumor volume measured by FDG-PET as a critical prognostic biomarker in patients with advanced non-small cell lung cancer undergoing first-line immunotherapy and chemotherapy. By transcending conventional metabolic metrics and focusing on holistic volumetric parameters, this research pioneers actionable insights that could transform patient management and outcomes in this formidable disease.

Subject of Research: Metabolic tumor burden assessment via FDG-PET as prognostic biomarkers in advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy.

Article Title: Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy.

Article References:
Obata, T., Norikane, T., Manabe, Y. et al. Torso FDG-PET parameters as prognostic biomarkers for advanced non-small cell lung cancer patients undergoing first-line immunotherapy and chemotherapy. BMC Cancer 25, 1454 (2025). https://doi.org/10.1186/s12885-025-14873-8

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14873-8

The research was conducted retrospectively on a cohort of 171 patients diagnosed with advanced NSCLC who underwent combined immune checkpoint inhibitor (ICI) therapy and chemotherapy. The investigators meticulously gathered clinical data alongside peripheral blood inflammatory markers to construct predictive models that could serve as reliable biomarkers for therapy efficacy and prognosis. Their focus centered on the systemic inflammatory response, particularly examining the NLR, fibrinogen levels, and other hematologic indices as potential indicators of therapeutic success or failure.

Among patients receiving first-line ICI plus chemotherapy, the study identified a critical threshold for pre-treatment NLR: values exceeding 3.3 correlated strongly with diminished progression-free survival (PFS). Elevated fibrinogen levels (greater than 3.196 g/L) similarly signaled poorer treatment outcomes. These findings underscore the interplay between systemic inflammation and cancer progression, highlighting how an imbalanced immune milieu marked by neutrophilia relative to lymphocytes may foster an environment conducive to tumor resistance and progression.

Crucially, the researchers developed a composite prognostic score combining NLR and fibrinogen—termed the NLR-Fib (NF) score—which demonstrated superior predictive accuracy compared to programmed cell death ligand 1 (PD-L1) expression assessed from tumor biopsies. PD-L1 has traditionally been utilized as a biomarker to select candidates for immunotherapy, but its variability and limitations have prompted the search for alternative or complementary measures. The NF score, derived from routine blood tests, offers a noninvasive, cost-effective, and reproducible tool for risk stratification in clinical practice.

The study also delved into a subset of NSCLC patients harboring targetable oncogenic driver mutations and treated with ICI plus chemotherapy beyond the first line. Here, a slightly higher NLR threshold of 3.53 was indicative of worse therapeutic responses and independently predicted both progression-free and overall survival (OS). Interestingly, prior duration of tyrosine kinase inhibitor (TKI) therapy exceeding 12 months emerged as an independent favorable prognostic factor for overall survival. This observation suggests that sustained disease control with targeted agents before immunotherapy may prime tumors for better responsiveness.

Further complexity was added by the identification of other factors influencing outcomes in this patient group. Secondary mutations such as the epidermal growth factor receptor (EGFR) T790M variant were associated with reduced PFS, as were a platelet-to-lymphocyte ratio (PLR) above 196.81 and hypoalbuminemia with albumin levels below 40.25 g/L. These markers collectively reflect the tumor’s evolving biology and systemic host factors that potentially modulate therapeutic efficacy.

Building on these insights, the authors formulated another prognostic metric termed the NLR-TKI-PFS (NTP) score, incorporating NLR levels and prior TKI progression-free survival time. This score stratified patients into three distinct risk categories — favorable, intermediate, and poor — correlating with median OS of 21, 12, and 5.3 months, respectively. Such a tool holds promise for guiding personalized treatment decisions and counseling patients regarding their prognosis in advanced disease stages.

The impact of this study extends beyond its immediate clinical findings. It challenges the current reliance on tissue-based biomarkers like PD-L1, which are often hampered by tumor heterogeneity, sampling bias, and dynamic expression changes. By contrast, systemic inflammation markers measured through blood tests provide a holistic snapshot of the host-tumor interaction and can be serially monitored to adapt treatment strategies.

Moreover, the accessibility and cost-effectiveness of blood-based biomarkers ensure the applicability of these prognostic scores even in resource-limited settings. As immunotherapy revolutionizes oncology care worldwide, such practical tools are imperative to optimize patient outcomes, avoid unnecessary toxicities, and contain healthcare costs.

The biological rationale underpinning the prognostic significance of NLR and fibrinogen is grounded in their roles in cancer pathophysiology. Neutrophils promote tumor progression by secreting pro-angiogenic factors and immunosuppressive cytokines, while lymphocytes, particularly cytotoxic T cells, are critical for anti-tumor immunity. A high NLR thus reflects a state of immune dysregulation favoring tumor escape. Elevated fibrinogen, a key coagulation factor, is implicated in tumor metastasis and inflammatory processes, further aggravating disease progression.

Beyond the statistical associations, this study advocates for integrating inflammatory markers into comprehensive clinical algorithms. Such integration may improve patient selection for immunotherapy and inform the timing of therapeutic interventions, combining or sequencing agents to overcome resistance mechanisms.

Future directions informed by this work include prospective validation trials to confirm the robustness of the NF and NTP scores across diverse populations and treatment regimens. Additionally, research into mechanistic links between inflammation and immunotherapy response could unveil novel therapeutic targets, potentially allowing modulation of the inflammatory milieu to enhance treatment efficacy.

Importantly, this research touches upon the personalized medicine paradigm, where nuanced patient stratification transcends conventional histological and genetic classifications. By incorporating systemic factors reflective of the host-tumor ecosystem, clinicians can better predict clinical trajectories and tailor interventions accordingly.

In summary, the study published in BMC Cancer heralds a promising advance in the prognostication of advanced NSCLC patients receiving ICI plus chemotherapy. Through innovative use of simple hematologic parameters, it provides a window into the complex interplay between cancer, host immunity, and treatment response. These insights bear the potential to refine therapeutic precision, improve survival outcomes, and ultimately transform patient care paradigms in oncology.

Subject of Research: Prognostic biomarkers in advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.

Article Title: Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.

Article References:
Liao, S., Sun, H., Lu, H. et al. Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.
BMC Cancer 25, 697 (2025). https://doi.org/10.1186/s12885-025-13811-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-13811-y